ロード中...

The Evolving Role of Monoclonal Antibodies in Colorectal Cancer: Early Presumptions and Impact on Clinical Trial Development

Targeted biologic agents have an established role in treating metastatic colorectal cancer (mCRC). Bevacizumab, a recombinant monoclonal antibody against the vascular endothelial growth factor ligand is approved by the U.S. Food and Drug Administration (FDA) for bevacizumab-naïve patients. Cetuximab...

詳細記述

保存先:
書誌詳細
第一著者: Eng, Cathy
フォーマット: Artigo
言語:Inglês
出版事項: AlphaMed Press 2010
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227885/
https://ncbi.nlm.nih.gov/pubmed/20067946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0167
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!